Kura Oncology (KURA) Asset Utilization Ratio (2025 - 2026)
Kura Oncology (KURA) reported Asset Utilization Ratio of 0.1 for Q1 2026, up 5.92% quarter-over-quarter from 0.1 in Q4 2025.
Kura Oncology (KURA) Asset Utilization Ratio (2025 - 2026) Analysis & Trends
Kura Oncology (KURA) has 2 years of Asset Utilization Ratio data on file, last reported at 0.1 in Q1 2026.
- Asset Utilization Ratio for Q1 2026 came in at 0.1, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 0.1 (changed N/A YoY), and the FY2025 annual result was 0.09, up 1.05% from the prior year.
- Asset Utilization Ratio improved to 0.1 in Q1 2026 per KURA's latest filing, from 0.1 in the prior quarter.
- Over five years, Asset Utilization Ratio peaked at 0.1 in Q1 2026 and troughed at 0.1 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 0.55 |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 0.60 |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | 1,422.00 |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 0.47 |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Kura Oncology | 802.81 Mn | 802.81 Mn | 18.00 Mn | 0.10 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.10 |
| Dec 31, 2025 | 0.10 |